Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
Conditions
Clinically Significant Prostate CancerSummary
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
Locations
1 location Found with status Recruiting
Status
- RECRUITING
Contact Person
- Qiang Zhang, MD.
- +1 312 503 2891
- [email protected]
Study Chair
- Weijun Qin, MD.
Eligibility Criteria
Inclusion Criteria:
1. Blood prostate-specific antigen PSA>4ng/dl;
2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging.
3. The patient is willing to undergo prostate biopsy.
Exclusion Criteria:
1. Previous diagnosis of prostate cancer through prostate biopsy;
2. History of other malignant tumors in the past two years;
3. According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment
Study Plan
Study Cohort
The experimental arm receiving diagnosis from serum RNA combination
Outcome Measures
Primary Outcome Measures
The diagnostic efficacy of plasma exo-RNA panel alone in diagnosing csPCa
Secondary Outcome Measures
Diagnostic efficacy of plasma exo-RNA panel in diagnosing csPCa and its comparison with other imaging methods or blood tests
Timeline
Last Updated
March 25, 2026Start Date
March 25, 2026Today
October 1, 2026Completion Date ( Estimated )
June 30, 2027
Sponsors of this trial
Lead Sponsor
Xijing HospitalCollaborating Sponsors
Shaanxi Provincial People's Hospital, Weinan Central Hospital, Shaanxi University of Chinese Medicine, LanZhou University, Qinghai University, Ningxia Medical University, Northwestern University, Yan'an University Affiliated Hospital, Air Force Military Medical University, China